HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
B-cell lymphoma 2 (BCL2)
BCL2 inhibitor venetoclax
HSP90 inhibitor PU-H71
MCL1 inhibitor S63845
acute myeloid leukemia (AML)
cell surface glycoprotein CD34
fms-like tyrosine kinase 3 (FLT3)
heat-shock protein 90 (HSP90)
myeloid cell leukemia 1 (MCL1)
stem cell factor receptor c-KIT (CD117)
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
received:
26
07
2023
revised:
11
08
2023
accepted:
21
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Targeting the molecular chaperone HSP90 and the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The HSP90 inhibitor PU-H71, MCL1 inhibitor S63845, and BCL2 inhibitor venetoclax were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells. AML cells represented all major morphologic and molecular subtypes including
Identifiants
pubmed: 37754227
pii: cimb45090443
doi: 10.3390/cimb45090443
pmc: PMC10529370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7011-7026Références
Nat Rev Mol Cell Biol. 2017 Jun;18(6):345-360
pubmed: 28429788
Nature. 2017 Jul 6;547(7661):104-108
pubmed: 28658204
Sci Rep. 2019 Aug 12;9(1):11697
pubmed: 31406210
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540760
Eur J Med Chem. 2022 Aug 5;238:114516
pubmed: 35691175
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Int J Mol Sci. 2022 Oct 20;23(20):
pubmed: 36293442
Mol Cell. 2019 May 16;74(4):831-843.e4
pubmed: 31027880
Ann Oncol. 1998 Feb;9(2):159-65
pubmed: 9553660
J Biol Chem. 2001 Nov 2;276(44):40583-90
pubmed: 11507088
Haematologica. 2011 Dec;96(12):1792-8
pubmed: 21933861
Cancers (Basel). 2019 Nov 12;11(11):
pubmed: 31718075
Cell Death Differ. 2017 May;24(5):878-888
pubmed: 28362427
Oncogene. 2016 Mar 24;35(12):1483-92
pubmed: 26096930
Cells. 2022 Aug 17;11(16):
pubmed: 36010632
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Cell Death Dis. 2019 Dec 4;10(12):917
pubmed: 31801941
Nat Cancer. 2020 Aug;1(8):826-839
pubmed: 33123685
Leukemia. 2021 Mar;35(3):691-700
pubmed: 32561839
Haematologica. 2019 Mar;104(3):516-523
pubmed: 30309854
Blood. 1998 Feb 1;91(3):991-1000
pubmed: 9446661
Oncogene. 2008 Apr 10;27(17):2445-55
pubmed: 17982489
Leukemia. 2006 Jul;20(7):1321-4
pubmed: 16642046
Cell Rep. 2015 Dec 15;13(10):2159-73
pubmed: 26628369
PLoS One. 2014 May 21;9(5):e97116
pubmed: 24849514
Front Oncol. 2022 Jan 21;12:829520
pubmed: 35127545
Pharmacol Res. 2015 Sep;99:202-16
pubmed: 26117427
Cancers (Basel). 2023 Feb 03;15(3):
pubmed: 36765939
Blood. 1993 Jun 1;81(11):3091-6
pubmed: 7684624
Pharmaceuticals (Basel). 2022 Mar 08;15(3):
pubmed: 35337118
Am J Hematol. 2006 Apr;81(4):227-35
pubmed: 16550517
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360855
NPJ Precis Oncol. 2021 May 26;5(1):44
pubmed: 34040147
Exp Hematol. 2020 Jun;86:1-14
pubmed: 32422232
Front Oncol. 2021 Feb 08;10:610820
pubmed: 33628731
Blood Adv. 2020 Nov 24;4(22):5681-5689
pubmed: 33211826
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Blood Rev. 2018 Nov;32(6):508-519
pubmed: 29728319
Blood Adv. 2022 Mar 8;6(5):1371-1380
pubmed: 34847232
Cancer Discov. 2020 Apr;10(4):536-551
pubmed: 31974170
Haematologica. 2020 Aug;105(8):2150-2163
pubmed: 31601689